Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

Autor: David R. Shaffer, Matthew H. Taylor, Alvaro Pinto, Daniel Heinrich, Chung-Han Lee, Chinyere E. Okpara, Øyvind Krohn Tennøe, Mehmet Asim Bilen, Donald A. Richards, Jane Wu, Randy F. Sweis, Arpit Rao, Rodolfo F. Perini, Amishi Yogesh Shah, Allen Lee Cohn, Jay Courtright, James J. Hsieh, Emmett V. Schmidt, Sara Gunnestad Ribe, Alan D. Smith, Drew W. Rasco, Robert J. Motzer, Regina Gironés Sarrió, Christopher Di Simone, Sharad Jain, Musaberk Goksel, Peter Kubiak, Nicholas J. Vogelzang

Publikováno v: LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Summary Background Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune checkpoint inhibitors (ICIs). Pembrolizu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::560f50f96435950099b910b1a10224ee
https://doi.org/10.1016/s1470-2045(21)00241-2